Sophie Paczesny, MD, PhD

Sophie Paczesny MD, PhD, is a professor in the Department of Microbiology and Immunology and co-leader of the Cancer Immunology Program at the Hollings Cancer Center at the Medical University of South Carolina.

Articles

Dr Paczesny on ST2 as a Biomarker for Acute GVHD Risk Post-Transplant

May 1st 2025

Sophie Paczesny MD, PhD, discussed the ability of ST2 to predict the risk of developing aGVHD or death following transplant.

The Evolving Field of GVHD Treatment

April 13th 2023

Sophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, share their expert perspectives on how the GVHD treatment landscape is evolving.

Key Investigational Approaches for Acute and Chronic GVHD

April 13th 2023

Drs Yi-Bin Chen and Sophie Paczesny highlight data from key investigational approaches presented at recent meetings.

Treatment Options for Steroid-Refractory Chronic GVHD

April 13th 2023

Yi-Bin Chen, MD, reviews the treatment options for patients with steroid-refractory chronic GVHD.

The Importance of Early Treatment of Chronic GVHD

April 13th 2023

Drs Paczesny and Chen explain the importance of treating chronic GVHD as early as possible, and whether steroids are still the standard first-line treatment.

Emerging Strategies for the Treatment of Acute GVHD

April 6th 2023

Sophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, detail novel strategies under investigation for the treatment of acute GVHD.

Frontline Treatment Options for Acute GVHD

April 6th 2023

Experts discuss the current options for treating acute GVHD, including the use of corticosteroids and their management.

Diagnosis and Stratification of Acute and Chronic GVHD

March 31st 2023

Drs Yi-Bin Chen and Sophie Paczesny review the diagnosis and staging of both acute and chronic GVHD, and the challenges clinicians may encounter.

Common Prophylaxis Regimens for GVHD

March 31st 2023

Yi-Bin Chen, MD, shares the most common GVHD prophylaxis regimens, and which regimen he typically chooses for his patients with GVHD.

Incidence and Risk Factors of Acute and Chronic GVHD

March 23rd 2023

Dr Sophie Paczesny details the incidence of graft versus host disease (GVHD) in patients receiving allogeneic transplants, and Dr Yi-Bin Chen describes the differing risk factors for acute and chronic GVHD.

Indications for Allogeneic Stem Cell Transplantation in the Treatment of Hematological Malignancies

March 23rd 2023

Sophie Paczesny, MD, PhD, explains which malignancies allogeneic transplantation can be used as a potentially curative treatment approach, and which patients are best suited for transplant.

Unmet Needs in GVHD Management

February 22nd 2022

Drs Sophie Paczesny, Hannah Choe, Nelson J. Chao, and Yi-Bin Chen share unmet needs in GVHD and advice for disease management.

Supportive Care for Steroid-Refractory Chronic GVHD Treatment

February 22nd 2022

Hannah Choe, MD, leads a review of the role of supportive care and a multidisciplinary team approach to care for the treatment of steroid-refractory chronic GVHD.

Clinical Manifestations of Chronic GVHD

February 22nd 2022

Drs Hannah Choe, Nelson J. Chao, Sophie Paczesny, and Yi-Bin Chen share their approach to treating patients with chronic GVHD who present initially with either scleroderma or bronchiolitis obliterans.

Future of Steroid-Refractory Chronic GVHD Treatment

February 15th 2022

Drs Hannah Choe, Yi-Bin Chen, Nelson J. Chao, and Sophie Paczesny explore emerging treatment options in the pipeline for the treatment of steroid-refractory chronic GVHD.

Treatment Selection for Steroid-Refractory GVHD

February 15th 2022

Hannah Choe, MD, leads the discussion on clinical experiences using off-label regimens to treat steroid-refractory chronic GVHD, and the optimal sequencing of therapy.

Steroid-Refractory Chronic GVHD: Management Strategies

February 8th 2022

Hannah Choe, MD; Sophie Paczesny, MD, PhD; and Nelson J. Chao, MD, MBA, review the use of current FDA approved therapies—ruxolitinib, ibrutinib, and belumosudil—for the treatment of steroid-refractory chronic GVHD.

Steroids for First-Line Treatment of Chronic GVHD

February 8th 2022

Yi-Bin Chen, MD, leads a discussion on the use of steroids as first-line treatment of chronic GVHD and when to switch therapy.

Overview of Steroid-Refractory Acute GVHD

February 1st 2022

Nelson J. Chao, MD, MBA, and Hannah Choe, MD, define steroid-refractory acute GVHD and current treatment options for the disease.

Evolution of Treatment for Acute GVHD

February 1st 2022

Sophie Paczesny, MD, PhD, provides insight on how strategies to treat acute GVHD have changed over time regarding outcomes and pathophysiology of disease.